{"filings":[{"id":469557,"accession_number":"0001493152-26-023666","cik":1424768,"company_name":"VYCOR MEDICAL INC","ticker":"VYCO","form_type":"8-K","filed_at":"2026-05-15T19:42:28+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vycor Medical Q1 2026 revenue up 5% to $458,540; turns to operating profit of $45,808","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $458,540 (+5% YoY); Vycor Medical division contributed $440,441.","Operating profit of $45,808 vs operating loss of $(12,806) in Q1 2025.","Non-GAAP operating profit $59,788, up from $20,388 YoY; cash expenses down to $315,365.","Gross margin steady at 82% for Vycor Medical; two new peer-reviewed VBAS studies published.","NovaVision revenue $18,099, still in development stage."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":458540.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2330000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103895,"accession_number":"0001493152-26-014079","cik":1424768,"company_name":"VYCOR MEDICAL INC","ticker":"VYCO","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vycor Medical annual revenue up 17% to $1.86M; operating profit swings to positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1,863,400 (+17% YoY); Vycor Medical division $1,796,070 (+18%), driven by international growth.","GAAP operating profit of $33,900 vs loss of $9,145 in 2024; non-GAAP operating profit $145,881 (+79%).","Gross margin 83% vs 89% in 2024 due to higher costs and international sales mix.","NovaVision revenue $67,330 (-8% YoY); study validated NeuroEyeCoach for home use.","Seven new peer-reviewed VBAS studies published in 2025; total clinical papers reach 50."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2330000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120176,"accession_number":"0001493152-25-023207","cik":1424768,"company_name":"VYCOR MEDICAL INC","ticker":"VYCO","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vycor Medical Q3 revenue $514K (+31% YoY); posts GAAP operating profit of $32K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $513,792, up 31% YoY; Vycor Medical division up 32% to $492K, mostly US growth.","GAAP operating profit of $32,085 in Q3 vs. loss in prior year; non-GAAP operating profit $60,162.","Nine-month revenue $1,446,523 (+28% YoY); non-GAAP operating profit $166,262 vs. $27,021 in 2024.","Gross margin dipped to 88% (Q3) and 84% (9-month) from 90% due to validation costs and international mix.","Three new peer-reviewed papers on VBAS published; NeuroEyeCoach study validates home-based therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1446523.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2330000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136741,"accession_number":"0001641172-25-022715","cik":1424768,"company_name":"VYCOR MEDICAL INC","ticker":"VYCO","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vycor Medical Q2 revenue up 22% to $496K; VBAS division drives growth with new international distribution","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $496,353 (+22% YoY); Vycor Medical (VBAS) up 24% to $481,788, led by international markets.","GAAP operating profit Q2 $51,146; non-GAAP operating profit $84,481, up from $31,859 in Q2 2024.","Gross margin fell to 83% from 91% due to validation/shipping costs of new production and sales mix.","Entered new distribution agreements for France and Spain during H1 2025, targeting key international markets.","Two new peer-reviewed VBAS clinical papers published in Q2; total now 48. NovaVision study validates NeuroEyeCoach for home/clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":932731.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2330000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153972,"accession_number":"0001641172-25-010594","cik":1424768,"company_name":"VYCOR MEDICAL INC","ticker":"VYCO","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vycor Medical Q1 revenue up 30% to $436k; operating profit turns positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $436,378 (+30% YoY); Vycor Medical division revenue $418,520 (+31%).","Non-GAAP cash operating profit of $21,619 vs $8,452 in prior year.","Gross margin 82% (down from 89%) due to validation, shipping costs and sales mix.","New distribution agreements signed for France and Spain; three VBAS clinical papers published.","NovaVision division revenue $17,858 (-3% YoY), remains in development stage."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":436378.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2330000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153971,"accession_number":"0001641172-25-004750","cik":1424768,"company_name":"VYCOR MEDICAL INC","ticker":"VYCO","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vycor Medical reports 2024 revenue up 9% to $1.59M; engages Maxim Group for strategic growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1,589,324 (+9% YoY); Vycor Medical division revenue up 10% to $1,515,744.","Gross margin 89%; non-GAAP cash operating expenses $1.34M (+$136K); non-GAAP operating profit $81,548 down from $111,084.","US hospital sales up 17% with 11 new hospitals; eight new peer-reviewed studies published on ViewSite Brain Access System.","Engaged Maxim Group LLC to assist with corporate strategy including M&A, partnerships, and potential uplisting to a US exchange.","Products manufactured in US; tariffs not expected to directly impact costs but may affect exports and raw material supply."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":436378.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2330000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}